Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review

BACKGROUND: Vedolizumab use in pediatrics is still off-label and the data are limited. We conducted a systematic review evaluating the efficacy and safety of vedolizumab in children and adolescents with inflammatory bowel disease (IBD). METHODS: PubMed, EMBASE and Cochrane databases were systematica...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Shengbo, Song, Yanqing, Zhang, Chunyan, Wang, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978350/
https://www.ncbi.nlm.nih.gov/pubmed/35379216
http://dx.doi.org/10.1186/s12887-022-03229-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978350/
https://www.ncbi.nlm.nih.gov/pubmed/35379216
http://dx.doi.org/10.1186/s12887-022-03229-x

Ejemplares similares